CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease.
Britney N LizamaClaire WilliamsHilary A NorthKiran PandeyDuc DuongValentina Di CaroAdam P MeccaKaj BlennowHenrik ZetterbergAllan I LeveyMichael GrundmanChristopher H van DyckAnthony O CaggianoNicholas T SeyfriedMary E HambyPublished in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2024)
This exploratory proteomics study identified candidate biomarkers of CT1812 in SPARC (NCT03493282) Comparative analyses identified biomarkers replicating across trials/cohorts Two independent Ph2 trial cohorts (SPARC and interim SHINE [NCT03507790; SHINE-A]) were used in a meta-analysis Amyloid beta (Aβ) & synaptic biology impacted by CT1812 and volumetric magnetic resonance imaging (vMRI) treatment-related correlates emerge Network analyses revealed sigma-2 receptor (S2R)-interacting proteins that may be "drivers" of changes.